Jade Biosciences, Inc. (JBIO) Insider Trading -- Recent Executive & Director Transactions

13 insiders reported 14 Form 4 transactions for Jade Biosciences, Inc. (JBIO) over the past 18 months (most recent 2026-02-13). Recent activity: King Andrew James (See Remarks) Buy 41,250 shares, Dahms Bradford D. (Chief Financial Officer) Buy 37,813 shares, Frohlich Tom (Chief Executive Officer) Buy 78,750 shares, Balta Elizabeth (See Remarks) Buy 28,125 shares, Harwin Peter Evan (Director) Buy 1.3M shares. Source: SEC Form 4.

DateInsiderTitleTypeSharesValue
2026-02-13King Andrew JamesSee RemarksBuy41,250$0
2026-02-13Dahms Bradford D.Chief Financial OfficerBuy37,813$0
2026-02-13Frohlich TomChief Executive OfficerBuy78,750$0
2026-02-13Balta ElizabethSee RemarksBuy28,125$0
2025-10-08Harwin Peter EvanDirectorBuy1.3M$12.2M
2025-10-08Fairmount Healthcare Fund II L.P.DirectorBuy1.3M$12.2M
2025-10-08Fairmount Funds Management LLCDirectorBuy1.3M$12.2M
2025-10-08Kiselak TomasDirectorBuy1.3M$12.2M
2025-10-08Fairmount Healthcare Co-Invest IV L.P.DirectorBuy1.3M$12.2M
2025-05-19Frohlich TomChief Executive OfficerBuy6,000$44,400
2025-04-30Shah Rajeev M.InsiderBuy1.1M$0
2025-04-30RA CAPITAL MANAGEMENT, L.P.InsiderBuy1.1M$0
2025-04-30Kolchinsky PeterInsiderBuy1.1M$0
2025-04-30RA Capital Healthcare Fund LPInsiderBuy1.1M$0

Source: SEC Form 4 filings · as of 2026-02-13